Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors With Survival in Patients With Hormone Receptor–Positive Metastatic Breast Cancer-Reference-Cited by-同舟云学术

Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors With Survival in Patients With Hormone Receptor–Positive Metastatic Breast Cancer

Published:2020-10-13 Issue:10 Volume:3 Page:e2020312
ISSN:2574-3805
Container-title:JAMA Network Open
language:en
Short-container-title:JAMA Netw Open

Author:

Li Jinming¹,Huo Xingfa¹,Zhao Fuxing¹,Ren Dengfeng¹,Ahmad Raees¹,Yuan Xinyue¹,Du Feng²,Zhao Jiuda¹

Affiliation:

1. Breast Disease Diagnosis and Treatment Center of Affiliated Hospital of Qinghai University & Affiliated Cancer Hospital of Qinghai University, Xining, China

2. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), The VIPII Gastrointestinal Cancer Division of the Medical Department, Peking University Cancer Hospital and Institute, Beijing, China

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2771442/li_2020_oi_200703_1605288276.26945.pdf

Reference40 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.;Bray;CA Cancer J Clin,2018

2. CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials.;Messina;Breast Cancer Res Treat,2018

3. Progression-free survival with endocrine-based therapies following progression on non-steroidal aromatase inhibitor among postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative metastatic breast cancer: a network meta-analysis.;Ayyagari;Curr Med Res Opin,2018

4. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.;Tripathy;Lancet Oncol,2018

5. Fatigue, alopecia and stomatitis among patients with breast cancer receiving cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis.;Lasheen;Expert Rev Anticancer Ther,2017

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adjuvant and neoadjuvant therapy with or without CDK4/6 inhibitors in HR+/HER2- early breast cancer: a systematic review and meta-analysis;Frontiers in Pharmacology;2024-09-12

2. Comparative analysis of adverse events associated with CDK4/6 inhibitors based on FDA’s adverse event reporting system: a case control pharmacovigilance study;BMC Pharmacology and Toxicology;2024-08-09

3. A Canadian real world prospective observational study assessing the impact of hormone therapy ± targeted therapy in the treatment of HR+ HER2- advanced breast cancer;2024-07-23

4. Mexican breast cancer consensus. Management of advanced breast cancer;Gaceta Mexicana de Oncolog�a;2024-06-25

5. Real-world experience with CDK4-6 inhibition in the old and oldest old with a diagnosis of breast cancer;Seminars in Oncology;2024-06